FENC

Business Context and Reporting Period

Company: Adherex Technologies Inc. (Note: Request metadata listed "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Period: Quarterly Report (Form 10-Q) for the three months ended March 31, 2011.
Business Stage: Development-stage biopharmaceutical company focused on cancer therapeutics (specifically eniluracil, STS, and ADH-1).
Going Concern: The filing explicitly states substantial doubt regarding the company's ability to continue as a going concern due to an accumulated deficit of $105.4 million and a history of negative cash flows. Additional funding is required to continue operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Income vs. Loss: The company reported a net income of $4.7 million in Q1 2011, a reversal from the $0.4 million net loss in Q1 2010. This income was not operational; it was driven almost entirely by a $5.7 million unrealized/realized gain on derivative warrants.
• Operating Expenses: Operating expenses increased by 179% (from $366k to $1.021 million). This increase is attributed to ramp-up costs for the Phase II clinical trial of eniluracil and professional fees related to a rights offering.
• Liquidity: Cash and cash equivalents decreased by approximately $0.9 million from the prior year-end ($5.9M to $5.0M) due to increased clinical trial spending and rights offering expenses, despite the rights offering proceeds being recorded as a receivable ($2.5M) at quarter-end.
• Derivative Liability: The derivative warrant liability decreased by $3.1 million (from $10.45M to $7.37M), reflecting the fair value adjustment that generated the non-cash gain.

Guidance, Outlook, Risks, and Unusual Items

• Unusual Items: The $5.7 million gain on derivatives is a non-cash item resulting from the revaluation of warrants denominated in Canadian dollars (functional currency is USD). This includes a $5.1 million unrealized gain and a $0.6 million realized gain from the expiration of rights offering derivatives.
• Outlook: Management expects proceeds from the April 2010 private placement and the March 2011 rights offering to fund a Phase II trial for eniluracil involving approximately 140 patients. The trial began patient enrollment in Russia in April 2011.
• Risks:
  • Capital Needs: The company requires substantial additional funding to continue operations and complete clinical trials. Failure to raise capital could force a curtailment of activities or shutdown.
  • Internal Controls: Management identified two material weaknesses in internal controls: lack of segregation of duties (one full-time employee handles all accounting) and insufficient personnel with technical GAAP knowledge.
  • Delisting Risk: The company faces potential delisting from the Toronto Stock Exchange if it fails to meet market capitalization or other listing standards.

Investor Verification Checklist

• Derivative Accounting: Verify the valuation assumptions (Black-Scholes model inputs) used to calculate the $5.7 million gain on derivatives, as this is the sole driver of profitability.
• Cash Burn Rate: Confirm the actual cash burn rate excluding non-cash derivative gains; operating cash outflow was $1.0 million for the quarter.
• Subscription Receivable: Verify the collection status of the $2.5 million subscription receivable from the rights offering, which was recorded as an asset but collected post-quarter-end.
• Internal Control Remediation: Assess the timeline and funding required to remediate the material weaknesses in financial reporting controls.
• Clinical Trial Milestones: Monitor the enrollment progress and results of the Phase II eniluracil trial in Russia, as future funding is contingent on these results.